Clariant AG Q2 2026 Results Overview
Clariant AG (SIX:CLN) reported second‑quarter 2026 adjusted EBITDA of CHF 171 million, surpassing analyst expectations of CHF 152 million by 13%. The quarter’s free‑cash‑flow conversion reached 52%, exceeding the company’s internal target of 40%.
The firm raised its cost‑savings target to CHF 100 million, up from the previously stated CHF 80 million, reflecting confidence after the earnings beat. Clariant reaffirmed its 2026 guidance, projecting local‑currency sales to be roughly flat, with an anticipated negative foreign‑exchange impact of 3‑5% and an EBITDA margin of approximately 18%.
Group‑wide sales totaled CHF 941 million, modestly above the consensus estimate of CHF 915 million. On a local‑currency basis, organic sales declined 0.3%, driven by a 3.3% volume contraction offset by a 3% price increase; currency translation effects reduced sales by 2.4%.
Division Performance
- Care Chemicals: Adjusted EBITDA of CHF 104 million, 13% above the analyst forecast of CHF 92 million; sales of CHF 504 million, up 2.5% locally.
- Catalysts: Adjusted EBITDA of CHF 33 million, beating the CHF 24 million estimate by 36%; sales fell to CHF 176 million, down 13.3% on a local‑currency basis.
- Adsorbents & Additives: Adjusted EBITDA of CHF 51 million, surpassing the CHF 46 million expectation; sales reached CHF 261 million, up 5.3% locally.
Operating cash flow for the first half of 2026 increased to CHF 193 million, compared with CHF 172 million in the same period of the prior year. Net debt stood at CHF 1,493 million, representing a 2.2× net‑debt‑to‑EBITDA ratio.